Key Takeaways
- CBER Director Peter Marks told a Jefferies conference in London that the FDA's high standards would be preserved during the second Trump Administration.
- Marks also said that he would stay at the agency "as long as I'm considered to be welcome."
- But he conceded that CBER may be able to reduce some cell and gene therapy regulation.
While biopharma share prices plummeted recently after President-elect Donald Trump promised to let Robert F. Kennedy Jr. “go wild” reforming government health programs, a senior US Food and...
Peter Marks, director of the FDA’s Center for Biologics Evaluation and Research, told the Jefferies healthcare conference in London on 21 November that he did not fear the worst, despite...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?